Article
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.
Hepatology (Baltimore, Md.) - 1 Jun 2008
Ferenci Peter, Brunner Harald, Laferl Hermann, Scherzer Thomas-Matthias, Maieron Andreas, Strasser Michael, Fischer Gabriele, Hofer Harald, Bischof Martin, Stauber Rudolf, Gschwantler Michael, Steindl-Munda Petra, Staufer Katharina, Löschenberger Karin
Abstract excerpt
UNLABELLED: We compared the efficacy and tolerability of 24 weeks of treatment with ribavirin 800 mg/day (group A) or 400 mg/day (group B) plus peginterferon alfa-2a 180 mug/week in treatment-naive patients infected with hepatitis C virus (HCV) genotype 2 or 3. A total of 97 of 141 patients randomized to group A (68.8%, 95% confidence interval [CI] 60.5%-76.3%) and 90 of 141 patients randomized to group B (63.8;...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.